Wednesday, May 14, 2014
Friday, May 31, 2013
FDA warning Indian drug manufacturing units - Is it a retaliation to court ruling against Novartis
One after other drug manufacturing units of India getting warning letters or getting banned to manufacture licenses getting cancelled. Is this a systematic fight back (to the set back of patent disputes in favor of local generic manufacturers) by big pharma by their arm twisting techniques or is it real the plants are not following procedures.
Today Hospira's manufacturing unit in India received a warning letter from FDA concerning the drug safety i.e contamination of drugs manufactured at its facility in India.
Indian pharmaceutical companies have also recently come under the FDA's scrutiny after generic drugmakers Ranbaxy Laboratories and Wockhardt Ltd faced issues related to manufacturing practices. Incidentally Indian court's ruling against Novartis came in April and after that FDA is finding issues and issuing warning letters. Or is it simply they have not followed the procedures.
Ranbaxy earlier this month agreed to pay $500 million in civil and criminal fines under a settlement agreement with the U.S. Department of Justice, after it pleaded guilty to three felony counts related to the manufacture of drugs at two Indian locations.
The FDA imposed an "import alert" on a plant operated by Wockhardt in the western state of Maharashtra on May 22.
As in the case of Hospira plant which is bought by Hospira from India-based Orchid Chemicals & Pharmaceuticals Ltd , the FDA said it found that surfaces in the facility were not always sanitized prior to use and that sterile drug products were not protected from contamination
Today Hospira's manufacturing unit in India received a warning letter from FDA concerning the drug safety i.e contamination of drugs manufactured at its facility in India.
Indian pharmaceutical companies have also recently come under the FDA's scrutiny after generic drugmakers Ranbaxy Laboratories and Wockhardt Ltd faced issues related to manufacturing practices. Incidentally Indian court's ruling against Novartis came in April and after that FDA is finding issues and issuing warning letters. Or is it simply they have not followed the procedures.
Ranbaxy earlier this month agreed to pay $500 million in civil and criminal fines under a settlement agreement with the U.S. Department of Justice, after it pleaded guilty to three felony counts related to the manufacture of drugs at two Indian locations.
The FDA imposed an "import alert" on a plant operated by Wockhardt in the western state of Maharashtra on May 22.
As in the case of Hospira plant which is bought by Hospira from India-based Orchid Chemicals & Pharmaceuticals Ltd , the FDA said it found that surfaces in the facility were not always sanitized prior to use and that sterile drug products were not protected from contamination
Thursday, May 30, 2013
New Seminars by ComplianceOnline - Sponsored posting
SOPs for FDA-Regulated Industry: Best Practices to Withstand FDA Expectations: 2-day In-person Seminar - Cambridge, MA June 20/21
Computer System Validation - Reduce Costs and Avoid 483s: 2-day In-person Seminar - San Francisco, CA - June 20/21 and Philadelphia, PA - Sept 26/27
The Sunshine Act - Have you seen the light? What you need to know to get prepared for August 1, 2013. The clock is ticking. Get prepared now, before it's too late! : One-day In-person Seminar - River North, IL June 21
Conducting Effective Investigation of Out-of-Specs and Atypical Laboratory Data: One and a Half day In-Person Seminar - Philadelphia, PA July 11/12
A Comprehensive View of FDA Regulations for Medical Devices: 2 - Day In-Person Seminar - Boston, MA July 30/31
Understanding and Implementing the Medical Device Directive: 2-Day In-person Seminar - Boston, MA Aug 1/2
Root Cause and Root Cause Analysis and Out-Of-Specification (OOS) Training: 2-day In-person Seminar - London, UK Aug 15/16
Latin America: Regulatory Compliance Requirements for Life Science Products (Focus: Brazil, Mexico, Argentina): 2-day In-person Seminar - Philadelphia, PA Aug 22/23
GMP Compliance for Quality Control and Contract Laboratories: 2-day In-person Seminar - San Diego, CA Aug 26/27
Analytical Instrument Qualification and System Validation: 2- day In-person Seminar - Cambridge, MA Aug 29/30
Manufacturing and Branding Cosmetics – 5 Best Practices to Follow for Regulatory Compliance
- Determine if product is a cosmetic or drug
- Ensure cosmetics are not adulterated
- Brand cosmetics properly
- Establish a comprehensive product surveillance program
- Check ingredients are not on the prohibited and restricted list
Read in details for each best practices click here to down load this whitepaper
Subscribe to:
Posts (Atom)